Skip to main content
EBS
NYSE Life Sciences

Wiseek Filing Insight

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
3
Price
$8.14
Mkt Cap
$420.386M
52W Low
$4.71
52W High
$14.06
Market data snapshot near publication time

check_boxKey Events

  • No key events were highlighted for this filing.

auto_awesomeAnalysis

No analysis available.

At the time of this filing, EBS was trading at $8.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $420.4M. The 52-week trading range was $4.71 to $14.06. This filing was assessed with an importance score of 3 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EBS - Latest Insights

EBS
Apr 28, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
7
Emergent BioSolutions Secures $34.5M Manufacturing & Distribution Deal for Japanese Encephalitis Vaccine
Sentiment: Positive
View Wiseek Article
EBS
Apr 22, 2026, 4:50 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Emergent BioSolutions Defends Stock Plan Proposal Amid Dilution Concerns
Sentiment: Neutral
View Wiseek Article
EBS
Apr 16, 2026, 5:51 PM EDT
Filing Type: 8-K
Importance Score:
8
Emergent BioSolutions Secures $150M Term Loan, $75M Delayed Draw, Refinances Debt, and Amends ABL Facility
Sentiment: Neutral
View Wiseek Article
EBS
Apr 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
$150M Term Loan Refinanced, Maturities Extended to 2031, Interest Expense Reduced for Emergent BioSolutions
Sentiment: Positive
View Wiseek Article
EBS
Apr 09, 2026, 4:25 PM EDT
Source: GlobeNewswire
Importance Score:
7
Emergent BioSolutions Secures $18M CAD Contract for NARCAN® Nasal Spray in British Columbia
Sentiment: Positive
View Wiseek Article
EBS
Mar 25, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Emergent BioSolutions Secures Over $60M in New U.S. and International Government Contracts for Smallpox Countermeasures
Sentiment: Positive
View Wiseek Article
EBS
Mar 20, 2026, 4:51 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Emergent BioSolutions Seeks Shareholder Approval for Significant Equity Plan Expansion Amid Turnaround Efforts
Sentiment: Neutral
View Wiseek Article
EBS
Mar 03, 2026, 8:28 AM EST
Filing Type: 8-K
Importance Score:
7
Emergent BioSolutions Appoints Healthcare & Finance Veteran John D. Fowler, Jr. to Board, Strengthening Turnaround Efforts
Sentiment: Positive
View Wiseek Article
EBS
Feb 26, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Emergent BioSolutions Reports Mixed FY25 Results, Projects Significant Profitability Decline in 2026
Sentiment: Negative
View Wiseek Article
EBS
Jan 14, 2026, 5:13 PM EST
Filing Type: 8-K
Importance Score:
8
Emergent BioSolutions Reduces Debt by $100M, Highlights Strategic Progress at J.P. Morgan Conference
Sentiment: Positive
View Wiseek Article